The trial for Zenkuda™ (tarcocimab tedromer) met its primary endpoint with high statistical significance, showing that it can not only slow but significantly reverse the severity of the disease.
Primary Success Metric: 62.5% of patients treated with Zenkuda achieved a =2-step improvement in DRSS at Week 48, compared to only 3.3% in the control (sham) group. Disease Reversal: Approximately 13.7% of patients even achieved a =3-step improvement, whereas 0% of the control group did. Reduced Complications: The treatment led to an 85% reduction in the risk of developing sight-threatening complications like proliferative diabetic retinopathy or macular edema.
Impact on Treatment and Market Analysts and clinicians view these results as a potential "paradigm shift" for several reasons:
Extended Durability: The efficacy was achieved with an every 6-month dosing schedule, which is significantly less frequent than many current treatments that require monthly or bi-monthly injections.
Strong Safety Profile: The study reported 0% intraocular inflammation, a critical safety metric that has historically been a challenge for long-acting ocular therapies.
GLP-1 Compatibility: The results were consistent even in patients using GLP-1 medications (like Ozempic), which is vital as a large portion of the diabetic population now uses these drugs.
Regulatory Momentum: Following this "confirmatory" win (supporting the earlier GLOW1 study), Kodiak announced it now has a BLA-ready profile and intends to accelerate its FDA submission plans.
Market Data 
Markets 
AI
